A5037061841- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Colorectal and Anal Carcinomas
- Brain Metastases and Treatment
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
- Cancer Treatment and Pharmacology
- Colorectal Cancer Screening and Detection
- Radiopharmaceutical Chemistry and Applications
- MRI in cancer diagnosis
- Radiomics and Machine Learning in Medical Imaging
- Microscopic Colitis
- Management of metastatic bone disease
- Advanced X-ray and CT Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Systems, Economic Evaluations, Quality of Life
Aalborg University Hospital
2024
Aarhus University Hospital
2004-2019
Zealand University Hospital
2018
Odense University Hospital
2004
Vejle Sygehus
2004
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether would be non-inferior to the usual treatment.The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk II and III cancer underwent central randomisation minimisation centre, choice regimen, sex, disease site, N stage, T starting dose capecitabine. were assigned...
The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, no consensus on the optimal time from to chemotherapy.
Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, associated cumulative toxicity, characterised by chronic often irreversible neuropathy. To assess efficacy of 3-month versus 6-month cancer to compare health-related quality life cost-effectiveness durations. An international, randomised, open-label, non-inferiority, Phase III, parallel-group trial. A total 244...
Background The morphological changes seen during treatment with regorafenib represent challenges when evaluating response using RECIST. Computed tomography texture analysis (CTTA) has potential as a non-invasive functional imaging biomarker anti-angiogenetic therapies. Purpose To explore in three-dimensional tumor CTTA colorectal liver metastases (CRLM) cohort of patients metastatic cancer regorafenib. Material and Methods Twenty-seven CRLM were treated evaluated CTTA. Texture was applied...
Background . Advanced HCC is a clinical challenge with limited treatment options. The multikinase inhibitor sorafenib the first and only agent showing survival benefit in these patients. In this study we evaluate efficacy tolerability of an unselected patient population. Furthermore explore role alpha-fetoprotein ( α FP) as potential biomarker for correlation to survival. Methods Seventy-six patients advanced HCC, not eligible locoregional therapy, treated between 2007 2009 were included....
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus usually given 6 (6 adjuvant chemotherapy in colorectal cancer. In total, 6088 patients with fully resected high-risk stage II or III cancer were followed up for 3–8 years. within-trial analysis from a UK health-care perspective presented using resource use data, quality life (EQ-5D-3L),...
There is a need for biomarkers to improve the clinical benefit from systemic treatment of colorectal cancer. We designed prospective, study where patients receiving regorafenib as last-line had sequential blood samples drawn. Effect and toxicity was monitored. The primary endpoint progression free survival (PFS). Cell-free circulating tumor (ct) DNA measured either fraction with Neuropeptide Y (NPY) methylated or KRAS/NRAS/BRAF mutated ctDNA. One hundred were included three Danish centers....
Background. Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) vascular endothelial (VEGF) are valid targets in many solid tumours, they synergistic effects preclinical studies. Methods. In this multi-center phase II trial patients chemoresistant, metastatic cancer were treated erlotinib (150 mg daily) bevacizumab (10 mg/kg every two weeks). Primary endpoint was overall response rate (ORR). Secondary...
Objective: This clinical trial investigated the safety and efficacy of single-cycle pembrolizumab in patients with localized deficient mismatch repair (dMMR) colon cancer. Background: Neoadjuvant immunotherapy has induced remarkable rates pathological complete response dMMR However, optimal length type treatment are yet to be determined. Methods: was an investigator-initiated, multicenter, single-arm, phase II study (ClinicalTrials.gov: NCT05662527) investigating neoadjuvant stage I-III...
Malignancies in the upper gastrointestinal (UGI) tract are amongst most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI were treated erlotinib bevacizumab. The combination therapy could not be recommended an unselected population of chemo-refractory cancer. However, subpopulation did benefit therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A),...
BackgroundRECIST 1.1 presents challenges when evaluating treatment response to angiogenesis inhibitors. The objective rate, the effect of regorafenib, using RECIST 1.1, is < 2% and beneficial could erroneously be terminated. Dynamic contrast-enhanced computed tomography (DCE-CT) has potential as a non-invasive functional imaging biomarker, by quantifying this targeted therapy. PurposeTo evaluate three-dimensional (3D) tumor dynamic parameters representing microcirculation assessed DCE-CT...
e15541 Background: Regorafenib has a proven but small significant effect in refractory colorectal cancer. The objective of the present, post-marketing trial was to investigate clinical outcome Danish patients. Further, we aimed at identifying new tumor specific prognostic markers. Methods: Eligible patients with metastatic disease and progression on standard chemotherapy were enrolled prospectively. Patients received regorafenib daily for three weeks four week cycles. Effect evaluated by CT...
7116 Background: 611 chemonaive patients with advanced NSCLC from three oncologic centers were treated Carboplatin (AUC=5) and Vinorelbine (30 mg/m2 d.1+8) q3w as a standard regimen outside protocol March 1998 to January 2003. 47 had brain metastases at the time of chemotherapy Methods: Data retrospectively collected patient files. The outcome without compared Results: Among median age was 58 years (range 38–70 years). 25 (53%) men 22 (47%) women. Metastatic pattern metastases: Liver 11%....